Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes

[1]  M. Suarez‐Almazor,et al.  The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy , 2022, Frontiers in Oncology.

[2]  Douglas B. Johnson,et al.  Immune-checkpoint inhibitors: long-term implications of toxicity , 2022, Nature Reviews Clinical Oncology.

[3]  O. Lambotte,et al.  The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. , 2021, European journal of cancer.

[4]  Fengchun Zhang,et al.  Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis , 2021, Frontiers in Immunology.

[5]  M. Atkins,et al.  Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. , 2021, European urology oncology.

[6]  A. Villani,et al.  Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data , 2021, Journal for ImmunoTherapy of Cancer.

[7]  P. Ascierto,et al.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events , 2021, Journal for ImmunoTherapy of Cancer.

[8]  Y. Nakanishi,et al.  Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events , 2021, Scientific reports.

[9]  S. Friesland,et al.  Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. , 2021, European journal of cancer.

[10]  G. Miremont-Salamé,et al.  Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer , 2020, Journal for ImmunoTherapy of Cancer.

[11]  D. Planchard,et al.  Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI) , 2020, Cancers.

[12]  Li Zhang,et al.  Use of glucocorticoids in the management of immunotherapy‐related adverse effects , 2020, Thoracic cancer.

[13]  A. Ardizzoni,et al.  Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance , 2020, Targeted Oncology.

[14]  E. Calvo,et al.  Clinical Challenges of Immune Checkpoint Inhibitors. , 2020, Cancer cell.

[15]  T. Powles,et al.  Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events , 2020, British Journal of Cancer.

[16]  A. Cohen,et al.  Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. , 2020, JAMA oncology.

[17]  D. Schadendorf,et al.  Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo , 2020, JAMA oncology.

[18]  R. Uchi,et al.  Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. , 2019, Oral oncology.

[19]  P. Xing,et al.  Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis , 2019, Journal of Immunotherapy for Cancer.

[20]  Naoto Okada,et al.  Factors Associated With Immune Checkpoint Inhibitor-Related Myocarditis. , 2019, JAMA oncology.

[21]  G. Coukos,et al.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.

[22]  V. Torri,et al.  Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors , 2019, ESMO Open.

[23]  Ling-Long Tang,et al.  Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis , 2018, British Medical Journal.

[24]  N. Pennell,et al.  Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  R. Sullivan,et al.  High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma , 2018, Cancer.

[26]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[27]  Kaoru Tanaka,et al.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.

[28]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.